MEI Pharma will present at the HC Wainwright Global Investment Conference 2022

SAN DIEGO, May 17, 2022–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing novel cancer therapies, today announced its participation in the 2022 HC Wainwright Global Investment Conference. will feature an updated corporate and business overview available for on-demand listening beginning Tuesday, May 24, 2022, 7:00 a.m. Eastern Time, which will be archived for 90 days.

The presentation can be accessed via the Events and Presentations page of the Investors section of the MEI Pharma website at An archived replay of the webcast will be available on the MEI Pharma website for at least 30 days after the live event ends.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new cancer therapies. MEI Pharma’s pipeline of drug candidates contains several clinical-stage assets, including zandelisib, currently in clinical trials that may support marketing approvals from the U.S. Food and Drug Administration and other authorities regulations globally. Each of the candidates in MEI Pharma’s pipeline leverages a different mechanism of action with the goal of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs, and (3) provide enhanced benefits to patients. patients, either as stand-alone treatments or in combination with other treatment options. For more information, please visit Follow us on twitter @MEI_Pharma and on LinkedIn.

Forward-looking statements

Under US law, a new drug cannot be marketed until it has undergone clinical studies and has been approved by the FDA as safe and effective for its intended use. Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the results of our clinical trials with zandelisib. , the expected timing of our submission of a marketing application to the FDA for zandelisib, the expected timing of the release of final study data for our TIDAL Phase 2 trial, the timing and success of the registration for our Phase 3 COASTAL trial, our projected financial condition and expected cash flow, the overall progress of our product candidates in clinical trials, and our plans for further development of our product candidates. In some cases we may use terms such as “predicts”, “believes”, “potential”, “continues”, “anticipates”, “estimates”, “expects”, “plans”, “has intent to”, “may”, “could”, “could”, “probable”, “will”, “should” or other words that convey uncertainty of future events or results to identify these forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to , our inability to successfully commercialize our product candidates; the availability or desirability of utilizing the FDA’s accelerated approval pathway for our product candidates; final data from our preclinical studies and completed clinical trials may differ materially from intermediaries reported d ongoing studies and trials; costs and delays in the development and/or FDA approval of our product candidates, or failure to obtain such approval for our product candidates; uncertainties or differences in the interpretation of clinical trial results; the risk that our clinical trials will be interrupted or delayed for any reason, including for safety, tolerability, recruitment, manufacturing or economic reasons; the impact of the COVID-19 pandemic on our industry and individual businesses, including our counterparties, supply chain, execution of our clinical development programs, access to funding and resource allocation governmental; our inability to maintain or enter into, and risks resulting from our reliance on, collaboration or contractual arrangements necessary for the development, manufacture, merchandising, marketing, sale and distribution of any product; competitive factors; our failure to protect our patents or proprietary rights and to obtain necessary patent and intellectual property rights from third parties to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; failure of any product to achieve market acceptance; our inability to obtain any additional financing required; technological changes; government regulations; changes in industry practices; and occasional events. We do not intend to update these factors or publicly announce the results of any revisions to these forward-looking statements.

See the source version on


MEI Pharma, Inc.
David A. Walsey
Tel: 858-369-7104
[email protected]

Jason I. Spark
Channel Communications for MEI
Tel: 619-849-6005
[email protected]

Comments are closed.